EUCTR2006-006808-11-IT进行中（未招募）1 期
Phase II study of 90Y ibritumomab tiuxetan (Zevalin) in patients with untreated follicular non-Hodgkin's lymphoma. - ZEUS
AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA0 个研究点开始时间: 2007年6月15日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Confirmed histological (according to the REAL/WHO classification) CD20 positive follicular, grade 1 or 2, non-Hodgkin's lymphoma, stage II bulky (node > 5 cm), III or IV at diagnosis time point; - Age > 18 years; - World Health Organization (WHO) performance status of 0 to 2; - Bone marrow involvement of disease 25% (measurement of bone marrow biopsy); - Platelet count of 150,000 x 103/ml or higher; - Haemoglobin (Hb) of 9 g/dl (90 g/l) or higher; - At least one bidimensionally measurable lesion (according to CT-scan); - Life expectancy of at least 3 months; - Written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Any prior anticancer treatment for NHL; - Prior radiation therapy; - Prior myeloabletive therapy; - Any other malignancy or history of prior malignancy except non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma within the past ten years; - Presence of syntomatic CNS lynphoma; - Patients with known HIV positivity; - Patients with known active infection uncontrolled by treatment; - Patients with pleural effusion or ascites; - Patients with abnormal liver function: total bilirubin > 1.5 x upper limits of normal (ULN) or ALAT >2.5 x ULN; - Patients with abnormal renal function: serum creatinine > 2.5 x ULN; - IgG < 3 g/l; - Known hypersensitivity to murine antibodies or proteins; - Pregnant or breast feeding female patients, or adult reproductive potential not employing an effective method of birth control during study treatment and for at least 12 months thereafter; - Ongoing severe and/or uncontrolled medical disease (e.g. uncontrolled diabetes, congestive heart failure, myocardial infarction within 6 months prior to the study, severe uncontrolled hypertension, chronic renal disease, or active uncontrolled infection) which could compromise participation in the study; - Patients who received any investigational drugs less than 4 weeks before entry in this study; - Patients who underwent surgery within 4 weeks of entering the study or patients who have not as yet recovered from the side-effects of such treatment; - Patients with a history of psychiatric illness or condition which could interfere with their ability to understand the requirements of the study; - Patients unwilling or unable to comply with the protocol.
研究者
相似试验
已完成
2 期
Efficacy of ibritumomab tiuxetan (Zevalin) following remission induction therapy for relapse of follicular lymphomaFollicular lymphomaJPRN-UMIN000007950The University of Tokyo Hospital25
已完成
2 期
Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular LymphomaFollicular LymphomaNCT01493479The Christie NHS Foundation Trust76
进行中（未招募）
不适用
90Y ibritumomab tiuxetan (Zevalin®) in patients with extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma) - ZENOEUCTR2007-004289-42-GRational and Kapodistrian University of Athens40
进行中（未招募）
不适用
PHASE II STUDY OF 90Y-IBRITUMOMAB TIUXETAN AND FOTEMUSTINE ASSOCIATED WITH CYTARABINE ETOPOSIDE MELPHALAN AS CONDITIONING CHEMORADIOIMMUNOTHERAPY IN PATIENTS AFFECTED BY LYMPHOMA (HODGKIN AND NON-HODGKIN) CD20+ REFRACTORY/RELAPSED WITH MINIMAL RESIDUAL PERSISTANT DISEASE PRE-AUTOLOGOUS TRANSPLANT - Z-FEAMPATIENTS <= 65 YEARS AFFECTED BY LYMPHOMA (HODGKIN AND NON-HODGKIN) CD20+ REFRACTORY/RELAPSED WITH MINIMAL RESIDUAL PERSISTANT DISEASE PRE-AUTOLOGOUS TRANSPLANTMedDRA version: 9.1Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellMedDRA version: 9.1Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseEUCTR2008-006899-30-ITISTITUTI FISIOTERAPICI OSPITALIERI
进行中（未招募）
不适用
Yttrium Y90Ibritumomab Tiutexan (Zevalin)as a consolidation treatment for patients with high grade non-Hodgkin's lymphoma aged >60 years. - NDEUCTR2008-003828-38-ITAZIENDA OSPEDALIERA OSPEDALE S. SALVATORE